Intellectual Property,
Health Care & Hospital Law,
Civil Litigation
Aug. 27, 2021
Juno Therapeutics’ $1.2B cancer treatment patent infringement victory reversed
A federal circuit scrapped Juno Therapeutics’ $1.2B cancer treatment patent victory against Kite Pharma.
A federal appellate panel on Thursday reversed a $1.2 billion patent infringement verdict against a Santa Monica subsidiary of Gilead Sciences Inc. over cell therapy used to treat cancer.
A panel of the U.S. Court of Appeals for the Federal Circuit ruled that the written description of the patent on immunotherapy was inadequate. The ruling wipes out a victory in federal court in Los Angeles by Irell & Manella LLP partner Morgan Chu and...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In
Enewsletter Sign-up
Related Content
A Spate of Only-in-California Cases Shines Spotlight on Federal Judge
Philip S. Gutierrez
Central District (Los Angeles)